About Us

PROFARMA is a pharmaceutical manufacturer headquartered in Tirana, Albania.

Share:

PROFARMA is a pharmaceutical manufacturer headquartered in Tirana, Albania.

Established in 1948 as a small pharmaceutical laboratory specializing in injectable preparations and selected medicines, Profarma has contributed for more than 75 years to the development of the pharmaceutical sector by delivering safe, effective, and accessible medicines.

All operations are conducted in accordance with international regulatory requirements and Good Manufacturing Practice (GMP), with a strong commitment to continuously align with European standards.

Key Investments & Modern Facilities

Since relocating to its new 27,000 m² manufacturing facility in 2011, Profarma has invested close to €25 million, primarily in the Pharmaceutical Manufacturing Division.

These investments have focused on upgrading production technologies, strengthening quality control systems, and improving overall working conditions through the acquisition of advanced equipment and modern infrastructure.

Today, Profarma operates a modern pharmaceutical manufacturing facility equipped with advanced production and quality control technologies, ensuring high standards of efficiency, safety, and product quality.

Leadership in Albania

For decades, Profarma has been a cornerstone of pharmaceutical manufacturing in Albania.

Despite the emergence of new market entrants in recent years, Profarma remains the only manufacturer in the country with full-scale production capabilities and a broad product portfolio, ensuring consistent quality, reliability, and strong long-term partnerships.

Product Portfolio & Development

Today, Profarma offers a wide range of more than 350 pharmaceutical products across multiple therapeutic areas. The portfolio covers 12 ATC groups,  including medicines for the digestive tract and metabolism, cardiovascular system, nervous system, respiratory system, musculoskeletal system, dermatology, anti-infectives, and other therapeutic categories.

Through continuous development and product lifecycle management, Profarma expands its portfolio with new generic medicines and improved formulations designed to meet evolving healthcare needs.

Our Journey

1948

Founded as a pharmaceutical laboratory focused primarily on injectable medicines.

1956

Expansion into tablet production, injectable solutions and galenic formulations.

2000

Privatization and transformation into a joint-stock company

2005

Major investments in modern technology, including film-coated tablet production.

2008

Partnership with a German company, new investments.

2011

Inauguration of the new GMP-compliant manufacturing facility.

International Presence

In addition to serving the domestic market, Profarma is actively expanding its presence in international markets. The company collaborates with partners across the Southern Balkans, the Middle East, and North Africa, building long-term relationships based on quality, reliability, and regulatory compliance.